REFERENCES
- Donny EC, Walsh SL, Bigelow GE, Eissenberg T, Stitzer ML. High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans. Psychopharmacology. 2002;161: 202–212.
- Dasgupta N, Bailey EJ, Cicero T, Post-marketing surveillance of methadone and buprenorphine in the United States. Pain Med. 2010;11:1078–1091.
- Centers for Disease Control and Prevention (CDC). Vital signs: risk for overdose from methadone used for pain relief—United States, 1999–2010. MMWR Morb Mortal Wkly Rep. 2012;61:493–497.
- Webster LR, Cochella S, Dasgupta N, An analysis of the root causes for opioid-related overdose deaths in the United States. Pain Med. 2011;12:S26–S35.
- Kapur BM, Hutson JR, Chibber T, Luk A, Selby P. Methadone: a review of drug-drug and pathophysiological interactions. Crit Rev Clin Lab Sci. 2011;48:171–195.
- Madden ME, Shapiro SL. The methadone epidemic. Methadone-related deaths on the rise in Vermont. Am J Forensic Med Pathol. 2011;32:131–135.
- Jasinski DR, Preston KL. Comparison of intravenously administered methadone, morphine and heroin. Drug Alcohol Depend. 1986;17:301–310.
- Rosenblum A, Parrino M, Schnoll SH, Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug Alcohol Depend. 2007;90:64–71.